Menu
Back to User profile » Prof. Dr. Christoph Correll
Papers published by Prof. Dr. Christoph Correll:
Personal and Social Functioning and Health-Related Quality of Life in Patients with Schizophrenia Treated with the Long-Acting Injectable Antipsychotic Risperidone ISM
Litman R, Naber D, Anta L, Martínez J, Filts Y, Correll CU
Neuropsychiatric Disease and Treatment 2023, 19:219-232
Published Date: 25 January 2023
Treatment Approaches for First Episode and Early-Phase Schizophrenia in Adolescents and Young Adults: A Delphi Consensus Report from Europe
Correll CU, Fusar-Poli P, Leucht S, Karow A, Maric N, Moreno C, Nordentoft M, Raballo A
Neuropsychiatric Disease and Treatment 2022, 18:201-219
Published Date: 9 February 2022
Negative Symptoms in Schizophrenia: A Review and Clinical Guide for Recognition, Assessment, and Treatment
Correll CU, Schooler NR
Neuropsychiatric Disease and Treatment 2020, 16:519-534
Published Date: 21 February 2020
Relationship between the timing of relapse and plasma drug levels following discontinuation of cariprazine treatment in patients with schizophrenia: indirect comparison with other second-generation antipsychotics after treatment discontinuation
Correll CU, Jain R, Meyer JM, Periclou A, Carrothers T, Barabássy Á, Patel M, Earley W
Neuropsychiatric Disease and Treatment 2019, 15:2537-2550
Published Date: 30 August 2019
Clinical relevance of paliperidone palmitate 3-monthly in treating schizophrenia
Mathews M, Gopal S, Nuamah I, Hargarter L, Savitz AJ, Kim E, Tan W, Soares B, Correll CU
Neuropsychiatric Disease and Treatment 2019, 15:1365-1379
Published Date: 21 May 2019
Identifying patients and clinical scenarios for use of long-acting injectable antipsychotics – expert consensus survey part 1
Sajatovic M, Ross R, Legacy SN, Correll CU, Kane JM, DiBiasi F, Fitzgerald H, Byerly M
Neuropsychiatric Disease and Treatment 2018, 14:1463-1474
Published Date: 8 June 2018
Initiating/maintaining long-acting injectable antipsychotics in schizophrenia/schizoaffective or bipolar disorder – expert consensus survey part 2
Sajatovic M, Ross R, Legacy SN, Byerly M, Kane JM, DiBiasi F, Fitzgerald H, Correll CU
Neuropsychiatric Disease and Treatment 2018, 14:1475-1492
Published Date: 8 June 2018
Treatment of tardive dyskinesia with VMAT-2 inhibitors: a systematic review and meta-analysis of randomized controlled trials
Solmi M, Pigato G, Kane JM, Correll CU
Drug Design, Development and Therapy 2018, 12:1215-1238
Published Date: 14 May 2018
Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review
Solmi M, Murru A, Pacchiarotti I, Undurraga J, Veronese N, Fornaro M, Stubbs B, Monaco F, Vieta E, Seeman MV, Correll CU, Carvalho AF
Therapeutics and Clinical Risk Management 2017, 13:757-777
Published Date: 29 June 2017
Schizophrenia relapse after stopping olanzapine treatment during pregnancy: a case report
Ifteni P, Moga MA, Burtea V, Correll CU
Therapeutics and Clinical Risk Management 2014, 10:901-904
Published Date: 23 October 2014